| ID | 68941 |
| FullText URL | |
| Author |
OTANI, YUSUKE
Department of Pathology, Beth Israel Deaconess Medical Center
MAEKAWA, MASAKI
Department of Pathology, Beth Israel Deaconess Medical Center
TANAKA, ATSUSHI
Department of Pathology, Beth Israel Deaconess Medical Center
PEÑA, TIRSO
Department of Pathology, Beth Israel Deaconess Medical Center
CHIN, VANESSA D.
UMass Chan Medical School, UMass Memorial Medical Center
ROGACHEVSKAYA, ANNA
Department of Pathology, Beth Israel Deaconess Medical Center
TOYOOKA, SHINICHI
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
ROEHRL, MICHAEL H.
Department of Pathology, Beth Israel Deaconess Medical Center
FUJIMURA, ATSUSHI
Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
researchmap
|
| Abstract | Background/Aim: Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of C1orf50 (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.
Materials and Methods: We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA). Results: Elevated expression levels of C1orf50 correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma. Conclusion: This study is the first to identify C1orf50 as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50’s impact on melanoma progression and patient prognosis. |
| Keywords | C1orf50
melanoma
cancer stem cells
YAP/TAZ
|
| Published Date | 2025-06-26
|
| Publication Title |
Cancer Genomics & Proteomics
|
| Volume | volume22
|
| Issue | issue4
|
| Publisher | International Institute of Anticancer Research
|
| Start Page | 510
|
| End Page | 524
|
| ISSN | 1109-6535
|
| NCID | AA11952487
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | ©2025 The Author(s).
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Related Url | isVersionOf https://doi.org/10.21873/cgp.20518
|
| License | https://creativecommons.org/licenses/by-nc-nd/4.0
|
| 助成情報 |
23K06676:
乳癌進展におけるメカノ応答性翻訳センサーの分子機構の解明と抗癌剤開発基盤の創成
( 文部科学省 / Ministry of Education )
19cm0106143:
tRNAエピトランスクリプトーム創薬で実現するがん幹細胞標的型抗がん剤の開発
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
22cm0106179:
次世代抗がん剤の創成を目指したtRNAエピトランスクリプトーム阻害剤の開発
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
( 公益財団法人内藤記念科学振興財団 / Naito Foundation )
|